Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Stock Picks For Healthy Returns
Nov 25, 2008 10:19 AM
- Pharmaceuticals Industry
Nov 21, 2008 04:22 PM
- Deficit Sets A Record - Analyst Blog
Nov 13, 2008 05:20 PM
- Wall Street Ends Mostly Higher, Energy Stocks Rally, Technology Drags
Oct 23, 2008 10:36 PM
- Sweden Joins The Rate Cut Party
Oct 23, 2008 02:09 PM
- Sweden Joins The Rate Cut Party
Oct 23, 2008 11:21 AM
- Notable Earnings Of The Day - 23 Oct
Oct 23, 2008 09:00 AM
- Cracks in the Ice - Analyst Blog
Oct 21, 2008 04:27 PM
- Google Goes Higher As Third-Quarter Profit Beats Estimates
Oct 18, 2008 02:36 PM
- The VIX and Volatility - Analyst Blog
Oct 17, 2008 03:52 PM
- Movers: Wells Fargo, Wachovia, Citigroup, ImClone, eBay
Oct 07, 2008 10:55 AM
- More Economists See U.S. In, Near Recession
Oct 07, 2008 07:56 AM
- Stocks Drop Amid Worries About Bailout Plan
Sep 24, 2008 10:57 AM
- Movers: AIG, WaMu, Circuit City, Lennar, GE
Sep 24, 2008 10:51 AM
- Movers: Lehman, WaMu, RIM, FedEx, ImClone Systems, GFI Group
Sep 11, 2008 10:58 AM
- Stocks Finish Higher After Durable-Goods Jump
Aug 28, 2008 10:55 AM
- Movers: Fannie Mae, Freddie Mac, Lehman, Amylin, Dollar Tree, J.Crew
Aug 28, 2008 10:55 AM
- Biz Quicks
Aug 05, 2008 11:55 AM
- ImClone hints at dim view of Bristol-Myers offer
Aug 04, 2008 11:57 AM
- Still Another Triple-Digit Swing on Wall Street
Aug 01, 2008 02:55 PM
- Zacks Analyst Blog Highlights: Pfizer, Inc., Bristol-Myers Squibb Co., The Hershey Co., Kimberly Clark Corp. And Companhia De Saneamento Basico Do Estado De SãO Paulo
Dec 01, 2008 07:12 AM
- Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
Nov 24, 2008 06:06 AM
- Seven Summits Research Releases Comments on JPM, MO, INFY, BMY, and ITU
Nov 21, 2008 11:16 AM
- Wall Street News Alert: Breaking News Alert -- CLTH! November 18, 2008
Nov 18, 2008 09:51 AM
- Bristol-Myers Squibb to Present at Healthcare Conference
Nov 13, 2008 09:12 AM
- Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
Nov 06, 2008 02:01 AM
- New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B
Nov 02, 2008 11:01 AM
- Bristol-Myers Squibb Foundation to Award $1.4 Million in Grants to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in Asia
Oct 31, 2008 10:02 AM
- ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
Oct 30, 2008 04:47 PM
- Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis
Oct 27, 2008 08:40 PM
- Form 4 GROBSTEIN MICHAEL For: Nov 21 (10K)
Nov 25, 2008 09:50 AM
- Form 4 BRISTOL MYERS SQUIBB CO For: Oct 31 Filed by: MCBRIDE ANTHONY A (10K)
Nov 04, 2008 10:46 AM
- Form 4 CORNELIUS JAMES M For: Oct 28 (10K)
Oct 30, 2008 02:55 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Oct 02 Filed by: MCBRIDE ANTHONY A (10K)
Oct 06, 2008 04:07 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Oct 02 Filed by: DANIELS BRIAN (10K)
Oct 06, 2008 04:07 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: GLIMEHER LAURIE H (10K)
Oct 02, 2008 04:32 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: Williams R Sanders (10K)
Oct 02, 2008 04:32 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: WEST TOGO D JR (10K)
Oct 02, 2008 04:27 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Sep 19 Filed by: SIGAL ELLIOT (10K)
Sep 23, 2008 05:24 PM
- Form 4 BRISTOL MYERS SQUIBB CO For: Sep 19 Filed by: HOOPER ANTHONY C (10K)
Sep 23, 2008 05:24 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
BMY
|
Compare to S&P
|
| YTD |
-21.95 %
|
27.88 %
|
| 4 Weeks |
0.73 %
|
8.88 %
|
| 12 Weeks |
-3.68 %
|
33.52 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 6.98 %
|
|
EPS Growth in Last Year: 21.05 %
|
|
Sales Growth in Last Quarter: 0.98 %
|
|
Sales Growth in Last Quarter: 4.04 %
|
|
|
